SLNO: 8-K · acquisition merger
Soleno Therapeutics, Inc. completed its merger with Neurocrine Biosciences, Inc. on May 18, 2026, following a tender offer that expired on May 15, 2026. Approximately 88.9% of outstanding shares (46,356,114 shares) were tendered at the offer price of $53.00 per share, satisfying the minimum condition for the transaction. Upon consummation, Soleno became a direct wholly-owned subsidiary of Neurocrine, and the company requested the delisting of its shares from the Nasdaq Capital Market. The company also filed for termination of registration under Section 12(g) of the Exchange Act, effectively ending its obligations as a public reporting company. In connection with the merger, all former directors and officers, including CEO Anish Bhatnagar, resigned. They were replaced by Neurocrine executives Darin M. Lippoldt and Matthew C. Abernethy. Existing equity awards were cashed out or cancelled according to the merger agreement terms.
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sale of Select Medical Holdings Corporation (SEM) for $16.50 per share. The firm is also investigating the sale of XOMA Royalty Corporation (XOMA) to Ligand Pharmaceuticals for $39.00 per share. Soleno Therapeutics, Inc. (SLNO) is being investigated for its sale to Neurocrine Biosciences for $53.00 per share in cash. KORE Group Holdings, Inc. (KORE) is under investigation for its sale to Searchlight Capital Partners and Abry Partners for $9.25 per share.
